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Abstract
Neonatal seizures are the most common neurological event in newborns, showing higher prevalence in preterm
than in full-term infants. In the majority of cases they represent acute symptomatic phenomena, the main etiologies
being intraventricular haemorrhage, hypoxic-ischemic encephalopathy, central nervous system infections and transient
metabolic derangements.
Current definition of neonatal seizures requires detection of paroxysmal EEG-changes, and in preterm newborns
the incidence of electrographic-only seizures seems to be particularly high, further stressing the crucial role of
electroencephalogram monitoring in this population. Imaging work-up includes an integration of serial cranial
ultrasound and brain magnetic resonance at term-equivalent age. Unfavourable outcomes following seizures in
preterm infants include death, neurodevelopmental impairment, epilepsy, cerebral palsy, hearing and visual
impairment. As experimental evidence suggests a detrimental role of seizures per se in determining subsequent
outcome, they should be promptly treated with the aim to reduce seizure burden and long-term disabilities.
However, neonatal seizures show low response to conventional anticonvulsant drugs, and this is even more
evident in preterm newborns, due to intrinsic developmental factors. As a consequence, as literature does not
provide any specific guidelines, due to the lack of robust evidence, off-label medications are often administered
in clinical practice.
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Background
Owing to improved neonatal care strategies and imple-
mented medical technology, the number of surviving
preterm newborns is increasing, even among extremely low
birth weight babies, although their morbidity rate is higher
compared to full-term infants [1]. Hence, new challenges
for the medical community include the management and
treatment of clinical conditions more often affecting
preterm infants, including neonatal seizures, which are the
most common neurological event in newborns. In fact,
there are several characteristics of preterm babies, such as
immature central nervous system development, low birth
weight and periventricular leukomalacia, that also represent
risk factors for seizures [2]. However, preterm newborns
are also more prone to develop severe complications and
they are less responsive to treatment with conventional
medications because of age-specific pharmacokinetic and
pharmacodynamic features [3]. In spite of these differences
between preterm and full-term infants, there is no differ-
ence in preterm versus full-term treatment strategies in
clinical practice, even if literature data suggest that the
same treatment might be less effective and more dangerous
in preterm than in full-term newborns. As a consequence,
second-line or off-label medications use has been increas-
ingly reported. Irrespective of controversies in their
management, neonatal seizures treatment is considered
very important in order to reduce morbidity, mortality and
seizure burden, and to improve the overall outcome in
these patients.
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Epidemiology
Neonatal seizures affect up to 1.5–3.5/1000 full-term
newborns and 10–130/1000 preterm infants [4]. There-
fore, the prevalence of seizures in preterm newborns is
higher than in full-term ones (22.2% compared to 0.5%)
[5], even if a recent study found that the incidence of
seizures is lower between 30 and 36 weeks of gestational
age than in both extremely preterm infants (<30w GA)
and in near-term ones (36-40w GA) [6].
Furthermore, time of seizure onset seems to be different
between preterm and full-term newborns: in fact, they tend
to occur later in premature infants. In particular, the first
suspected seizure is reported at a median age of 27 h of life
in full-term infants and at 14 days in preterm newborns
[7]. Moreover, there are some differences according to
gestational age: in a recent study mean seizure onset was
14.6 days (range 1–120 days, SD 20.4) in <29wGA new-
borns, compared to 5.2 days (range 1–37 days, SD 7.7) in
>29wGA ones [8]. In a further research, mean seizure on-
set was 8.3 days of life in infants with gestational age ≤
29 weeks, while it was earlier (3.2 days) in newborns with a
gestational age between 30 and 36 weeks [9]. This is likely
due to differing seizure etiologies [6, 8–10]. In particular,
seizures caused by intraventricular haemorrhage usually
occur during the first 24 h of life and many preterm
newborns’ seizures persist into the third day of life [11]. Es-
pecially if associated with parenchymal infarction, seizures
are most likely to occur in the latter part of the first week
of life. Other etiology of seizure in preterm are represented
by hypoxic-ischemic encephalopathy, central nervous sys-
tem infections and transient metabolic derangements [12].
Moreover, the rate of seizures seems to depend on the
method of ascertainment, as the prevalence of clinically-
defined seizures ranges from 0,30 [13] to 57.5 per 1000
births [14] while the prevalence of EEG-detected seizures
is 24% in premature infants [10].
Etiology
Intraventricular haemorrhage and its complications are the
main cause of neonatal seizures in very and extremely pre-
term newborns (< 32 wGA) [8, 10], and the risk increases
with increasing severity of brain injury (grades III and IV
intraventricular haemorrhage) [8, 15–17]. On the other
hand, in moderate and late preterm infants the majority of
seizures are caused by hypoxic-ischemic encephalopathy
[10] which shows 40–60% prevalence in near-term new-
borns with seizures [17, 18]. Additional acquired etiologies
include central nervous system or systemic infection (i.e.
meningitis, viral meningoencephalitis and sepsis) [8], other
acquired brain injuries (subarachnoid haemorrhage,
ischemic stroke), trauma, transient metabolic diseases (i.e.
hypoglycaemia in low birth weight infants, hypocalcaemia,
hypomagnesaemia, sodium imbalance in very low birth
weight ones) [12], drug withdrawal or poisoning [20].
Neonatal-onset epilepsies (of genetic origin) and inborn
errors of metabolism also need to be considered in the
differential diagnosis.
Pathophysiology
Various risk factors have been associated with seizures in
preterm newborns, such as lack of state changes on EEG
[21], intraventricular haemorrhage, periventricular leuko-
malacia, surgery, patent ductus arteriosus, necrotizing
enterocolitis, pulmonary diseases or respiratory distress
and low birth weight [19]. In particular, low birth weight
infants show a 9% increase in seizure rate for each week
decrease in gestational age [19].
However, the main reason why preterm infants are
prone to develop seizures is their brain immaturity [22].
Gamma-Aminobutyric acid (GABA) is crucial for neur-
onal maturation and activity-dependent integration into
circuits [23]. Immature neurons arecharacterized by high
neuronal chloride concentrations, deriving from the differ-
ent expression of the NKCC1 versus the KCC2 cation-
chloride cotransporters in immature versus mature
neurons [24, 25]. This causes GABAergic signaling to be
mainly excitatory and driven by NKCC1 receptors in
embryonic and early post-natal life [26]. Afterwards, the
GABAergic interneuronal network develops and switches
from excitatory to inhibitory. Neurophysiologically, there
is a concomitant emergence of more ‘continuous’ oscilla-
tions subsiding the spontaneous activity transients (SATs),
recorded in extremely preterm newborns [27].
Between 24 and 32 weeks of gestational age, premyeli-
nating oligodendrocyte progenitor cells are particularly
vulnerable to hypoxic-ischemic damage [28], due to the
interaction of immature blood flow autoregulation, imma-
ture vascular supply and heart-rate dependent cardiac
output [22, 29]. Consequently, white matter injury occurs
when other predisposing factors such as infections, inflam-
mations and disturbances in cerebral oxygenation overlap
with the intrinsic vulnerability of the premature brain [30].
Oligodendroglial damage causes impaired myelination,
while parenchymal haemorrhage or high grade intraven-
tricular haemorrhage cause projection and association
fibers injury. When changes affect subplate neurons, both
the cortex and its connections with the thalamus are
damaged [28], and this can lead to higher long-term
cortical excitability [31].
In particular, extremely low birth weight newborns often
display a passive cerebral blood flow [32]. As a conse-
quence, the occurrence of intraventricular haemorrhage is
more frequent, and various hypotheses have been proposed
to explain this higher risk. First of all, some conditions
such as pneumothorax, changes in head position and ven-
tilator asynchrony can cause impaired venous drainage,
thus facilitating haemorrhage. Second, sudden changes in
arterial blood pressure caused by sepsis, noxious stimuli,
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fluid boluses or inotropes can have the same effect, leading
to intraventricular haemorrhage [29].
Diagnosis
Neonatal seizures in newborns are clinically defined as
abnormal, stereotyped and paroxysmal dysfunctions in
the central nervous system, occurring within 44 weeks
of gestational age.
From a clinical point of view, neonatal seizures are di-
vided into clonic, myoclonic, tonic and subtle seizures.
Clonic seizures consist of repetitive, rhythmic (1–4/s)
contractions of muscle groups of the limbs, face or
trunk. They can be focal or multifocal. They are usually
electrically-confirmed. Myoclonic seizures are isolated or
repetitive contractions of proximal or distal muscles, less
regular and persistent than clonic jerks. They can be
generalized, focal or multifocal. Tonic seizures are classi-
fied as generalized or focal. Focal tonic seizures consist
of sustained, but transient, asymmetrical posturing of
the trunk or extremities or tonic eye deviation, while
generalized tonic seizures are bilateral symmetrical tonic
posturing (with flexor/extensor predominance or mixed).
Electrographic correlate is inconsistent for both seizure
types. Subtle seizures include motor automatisms (such
as chewing, swallowing, sucking, repetitive tongue
movements, “cycling”, “boxing”, “pedaling”, “swimming”)
and autonomic signs (changes in heart rate or breathing
pattern, flushing, salivation, pupil dilatation) [33].
Neurophysiologically a seizure is defined as the presence
of a paroxysmal EEG change with a clear onset and
termination, lasting at least 10 s, and an evolution in
frequency, morphology and amplitude.
As above said, the prevalence of neonatal seizures is
higher in preterm (22.2%) than in full-term newborns
(0.5%) [5] but studies about clinically-defined seizures show
a larger percentage of neonatal seizures than EEG-based
studies [34, 35], especially aEEG-based ones [11, 15]. For
example, a prospective study about infants born before the
32nd week of gestational age found a 5% incidence of neo-
natal seizures [36]. In contrast, 11.9% incidence has been
reported in studies on clinically-diagnosed seizures [6].
Clinical-only seizures (without any electrographic evi-
dence), are usually considered non-epileptic and related to
the loss of cortical inhibition on subcortical structures [37].
Paroxysmal non-epileptic motor phenomena should be
taken into consideration in the differential diagnosis [38].
No general consensus has been achieved on the defin-
ition of neonatal status epilepticus. A commonly adopted
definition considers it as continuous seizure activity last-
ing ≥30 min or the occurrence of recurrent seizures
≥50% of the recording time (1–3 h) [18]. For a recent
review on controversies regarding status epilepticus,
please refer to (Pavlidis, Pisani EJPN 2018) [39].
Monitoring of preterm newborns at increased risk
of seizures
If possible, a multimodal neurophysiological and neuro-
imaging approach is recommended in newborns [40].
Neurophysiologic monitoring: Conventional and
amplitude-integrated EEG
Literature points out the importance of EEG monitoring
in the context of suspected seizures, both for diagnosis
and to evaluate treatment efficacy.
Conventional video-EEG enables definition of seizure
onset, spread, duration and correlation with motor phe-
nomena. Therefore, it can differentiate paroxysmal non-
epileptic motor phenomena (not associated with any EEG
changes) and detect electrographic-only seizures [41]. It
can give early prognostic information, suggesting etiolo-
gies such as a focal injury or a diffuse pathology and indi-
cates severity of functional compromise [34, 38, 42, 43]. In
fact, background activity is a strong predictor of outcome,
in particular when serial recordings are performed [44].
Moreover, even after seizure confirmation, prolonged or
continuous monitoring are useful to quantify “seizure bur-
den” and to diagnose neonatal status epilepticus [45, 46].
EEG-monitoring is required to test anticonvulsants effi-
cacy, so it is recommended to continue EEG-recording for
at least 24 h of seizure freedom [47], and it is also advis-
able to monitor the newborn after drug discontinuation.
In addition, the literature suggests that amplitude-inte-
grated EEG (aEEG) might miss seizures originating far
from the electrodes or of short duration. It can also lead
to false positive results due to artefacts. Consequently, it is
mainly used as a screening tool, while conventional EEG
is recorded to improve sensitivity and specificity [48, 49].
In preterm newborns, the first EEG-recording is recom-
mended as soon as possible after birth, because its sensi-
tivity is higher in the first 48 h of life [50, 51].
Cranial ultrasound scan
Another non-invasive and low cost technique to de-
tect seizure etiology is cranial ultrasound scan (CUS).
Therefore, a scan protocol for preterm infants has
been proposed. In particular, a CUS is always recom-
mended at term equivalent age in preterm newborns
and, from the 23rd to the 35th week of GA, a CUS
should be performed in the first 24 h of life, then at
the first, second and third week of life. Additional
cranial ultrasound scans are recommended depending
on gestational age [52]. Moreover, CUS should be
integrated with brain magnetic resonance (MRI) at
term equivalent age when intraventricular haemor-
rhage, to detect ventriculomegaly, white matter injury
and cerebellar involvement [53, 54].
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Brain MRI
First of all, brain magnetic resonance imaging (MRI) can
recognize specific patterns in seizures due to structural
causes, for example related to central nervous system
infections [55]. Conventional brain MRI should be
performed in preterm newborns at term-equivalent age, to
gain more accurate information about ventriculomegaly,
white matter injury and cerebellar involvement in case of
uncomplicated intraventricular haemorrhage [53, 54]. In
contrast, when hypoxic-ischemic encephalopathy is the
seizures cause, brain injury can be detected earlier with
diffusion weighted imaging (DWI), while conventional
brain MRI shows a loss of grey-white matter differentiation
at the end of the first week of life [56].
Treatment
According to experimental and clinical data [57], pro-
longed seizures may contribute to poor neurological out-
come, thus they should be promptly treated in an attempt
to reduce long-term disabilities [58]. However, therapeutic
options for seizures in newborns are still unsatisfactory
[59] and the available evidence is poor [60].
Moreover, the literature does not provide any customized
treatment approach for premature newborns suffering
from neonatal seizures, even if several studies show a lower
response rate than in full-term infants, with poorer
prognosis. In fact, liver and renal function, but also central
nervous system development, are not complete in prema-
ture infants, leading to differences in drugs pharmacokinet-
ics and pharmacodynamics. Hence, potentially the same
treatment might be both less effective and more dangerous
in a preterm newborn than in a full-term one. However,
studies found no difference in treatment strategies accord-
ing to gestational age in clinical practice [61]. Conventional
GABAergic antiseizure medications are less effective in
newborns, because GABAergic signalling is mainly driven
by NKCC1 receptors, with an excitatory instead of inhibi-
tory effect [24, 26]. As a consequence, second-line or
off-label medications are increasingly administered to new-
borns and proposed in treatment algorithms, although the
underlying evidence is low [62]. The recommended
first-line choice is represented by phenobarbital in both
term and preterm infants (80% of cases), even if its efficacy
is approximately 50%, followed by phenytoin in 40% of
patients. This is based on the availability of randomized
controlled safety and efficacy data [63]. In the lack of
clear-cut evidence or guidance, when no response is ob-
tained with conventional antiseizure drugs, off-label agents
are often administered, such as levetiracetam, topiramate,
lidocaine and midazolam. [3, 62, 64, 65]. Studies about
pharmacokinetics and pharmacodynamic changes in pre-
term infants, report a longer half-life and a higher distribu-
tion volumes in preterm than in full-term newborns for
both first-line and second-line antiseizure medications
[66–69]. Anyway, it is important to notice that in recent
years, levetiracetam has been increasingly used for treat-
ment of neonatal seizures. Along with other papers [64,
70–73, 74], a recent retrospective analysis on preterm in-
fants treated with levetiracetam as first-line showed 57% of
seizure freedom at the end of the first week of life, without
requiring any other treatment, no adverse drug reactions
or laboratory abnormalities, suggesting that levetiracetam
can be a safe option in neonates [75].
Finally, no clear evidence on when to discontinue medi-
cations is available, although in the majority of newborns
therapy is continued after discharge from neonatal units
[10]. A recent perspective research demonstrates that in
neonates suffering from hypoxic-ischemic encephalopathy,
antiseizure medication discontinuation prior to discharge
did not increase the risk of seizures after discharge [75]. A
further recent study suggests to use the need for a second
antiseizure medication and time to seizure control to
determine when to discontinue phenobarbital, supporting
its early discontinuation [76].
Outcome and risk factors for unfavourable
outcome
Seizures in preterm newborns result in an increased risk
of developing several medical conditions with neurological
and intellectual disabilities. Recent papers show that,
thanks to innovations in neonatal care, there has been a
reduction in mortality, but, as a consequence, an increase
in morbidity [77, 78]. In fact, common unfavourable out-
comes include epilepsy, cerebral palsy [77], cognitive im-
pairment (intellectual disability and developmental delay,
64% vs 29% in preterm infants with seizures compared to
those without seizures), microcephaly [79], hearing (11%
vs 4% in preterm newborns without seizures) and vision
impairment (43% vs 14%).
Studies detect a normal long-term outcome in a small
percentage of patients (12–25%). In comparison, a normal
outcome is more common in both full-term infants suffer-
ing from seizures [18, 78, 80] and in preterm infants
without seizures [81].
In accordance with these data, mortality rate is higher in
preterm (32–35%) than in full-term newborns with seizures
(5.4–15%) [10, 80, 82] and in preterm infants without sei-
zures (5–16.6%) [35, 82]. Risk factors for mortality include
birth weight lower than 1000 g, birth at GA < 28 weeks and
severely abnormal background EEG patterns, such as iso-
electric or low voltage invariant activity, burst-suppression
or permanent discontinuous activity, and longer seizure
duration, namely status epilepticus [8, 9]. In the context of
status epilepticus, the mortality risk is higher in preterm
compared to full-term newborns (52,6% versus 17,8%), even
though, interestingly no statistically significant differences
between preterm and full-term infants with status
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epilepticus were documented, except for Apgar scores and
neurological examination [46].
Notably, background EEG pattern represents an inde-
pendent predictor of mortality [8]. When seizures are
exclusively subclinical, mortality rate is higher [7], while
late death (after 36 weeks of post-menstrual age) and
neuro-developmental impairment have been reported as
more frequent in patients with clinical seizures [82].
Additional risk factors for poor prognosis include male
sex, multiple birth, non-Caucasian newborns, low birth
weight [82] and poor response to anticonvulsant drugs
[7]. This latter factor has been associated with a higher
rate of later epilepsy, together with severely abnormal
cranial ultrasound scan and EEG (especially when the
ictal activity spreads to the contralateral hemisphere)
and status epilepticus [35, 43], as they underline more
severe brain injury. In particular, status epilepticus is an
independent predictor of unfavourable outcome, because
it is associated with subsequent epilepsy in both preterm
and full term infants [80]. Studies show that status
epilepticus is more frequent in preterm infants with
birth weight lower than 1000 g or between 1500 and
2499 g, with severely abnormal EEG traces and neuro-
logical examination [8, 46]. Anyway, it is important to
notice that preterm newborns with status epilepticus
show a lower incidence of post-neonatal epilepsy than
full-term ones [18], even if still as high as 40 times
higher than in the general population [78].
In contrast, cerebral palsy as an outcome in patients suf-
fering from neonatal seizures seems to be higher in pre-
term infants than in full-term newborns [77], especially
when prematurity is associated with periventricular leuko-
malacia, severe intraventricular haemorrhage, systemic
disease or infections [83, 84]. Regarding the administration
of steroids in newborns, there seems to be an increased
risk of cerebral palsy when they are administered after
birth, while the risk is lower if administered in the
antenatal period [83].
Furthermore, with respect to intellectual impairment
following neonatal seizures, evidence shows a high rate
of severe impairment (61%), with lower percentage of
moderate (22%) and mild (17%) impairment, without
statistically significant differences associated to gesta-
tional age [9]. The risk of cognitive impairment seems to
be higher in clinically-diagnosed than in EEG-diagnosed
seizures [78, 81].
Conclusion
Acute symptomatic neonatal seizures can be caused by
several conditions which should be detected because
prognosis largely depends on underlying etiology. The
most frequent cause in preterm infants is intraventricular
haemorrhage. Appropriate clinical and neurophysiologic
monitoring, neuroimaging techniques and improvement in
neurocritical care in the neonatal period are improving
management of infants with seizures, and their outcome,
especially mortality risk. However, the occurrence of
seizures in preterm newborns is still associated with poor
cognitive development, visual, hearing and motor impair-
ment, cerebral palsy and epilepsy. Early treatment should
be provided to neonates presenting seizures (even electrical
seizures) to reduce mortality and disabilities and to
improve long-term outcome especially in very and
extremely preterm newborns.
Future perspectives
In the future, research should be addressed to identify a
customized treatment for preterm newborns, consider-
ing their pharmacokinetic and pharmacodynamic
changes and brain developmental stages. Randomized
controlled studies are required in order to establish if
treatment strategies should be differentiated according
to gestational age and underlying etiology (and how)
with special emphasis on treatment duration and timing
of treatment discontinuation.
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